Back to All Topics
Research
Research Article
2 min read
On-Cycle Blood Work Monitoring
Laboratory testing protocols during active peptide use.
Introduction
Regular monitoring during peptide cycles ensures safety and enables protocol optimization.
On-Cycle Testing Schedule
Standard Schedule
| Timing | Tests | Purpose |
|---|---|---|
| Week 4 | Key markers | Early detection |
| Week 8 | Comprehensive | Mid-cycle assessment |
| Week 12 | Full panel | Pre-cycle end |
| As needed | Targeted | Symptom-driven |
Key Markers for Monitoring
| Marker | Frequency | Concern Threshold |
|---|---|---|
| IGF-1 | Every 4-8 weeks | >400 ng/mL |
| Fasting glucose | Every 4-8 weeks | >100 mg/dL |
| HbA1c | Every 8-12 weeks | Rising trend |
GH Secretagogue Specific
Priority Markers
| Marker | Rationale | Action Threshold |
|---|---|---|
| IGF-1 | GH pathway activity | Reduce dose if excessive |
| Fasting glucose | Insulin sensitivity | Dietary intervention |
| Fasting insulin | Resistance | Protocol adjustment |
Secondary Markers
| Marker | Concern | Response |
|---|---|---|
| Prolactin | Elevation possible | Evaluate compound |
| Thyroid function | Rare changes | Monitor if symptomatic |
| Liver enzymes | Unlikely affected | Baseline comparison |
IGF-1 Peptide Specific
Key Monitoring
| Marker | Rationale | Frequency |
|---|---|---|
| Blood glucose | Hypoglycemia risk | Regular |
| IGF-1 levels | Activity | Monthly |
| Symptoms | Hypoglycemia signs | Daily awareness |
Healing Peptide Monitoring
BPC-157/TB-500
| Marker | Necessity | Rationale |
|---|---|---|
| Routine panels | Optional | Limited systemic effects |
| Symptom tracking | Important | Efficacy assessment |
| Healing progress | Primary | Goal monitoring |
Interpreting Results
Response Matrix
| Finding | Meaning | Action |
|---|---|---|
| IGF-1 elevated appropriately | Peptide active | Continue |
| IGF-1 excessive (>400) | Over-response | Reduce dose |
| Glucose rising | Insulin sensitivity | Dietary adjustment |
| No IGF-1 change | Possible quality issue | Evaluate source |
Red Flags
| Finding | Concern Level | Immediate Action |
|---|---|---|
| IGF-1 >500 ng/mL | High | Discontinue |
| Glucose >126 mg/dL | High | Medical evaluation |
| New symptoms | Variable | Investigate |
Conclusion
Consistent on-cycle monitoring ensures safety and optimizes protocol effectiveness.
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.